Boston Partners Cuts Stock Holdings in Haemonetics Co. (NYSE:HAE)

Boston Partners lowered its stake in shares of Haemonetics Co. (NYSE:HAE) by 37.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 444,180 shares of the medical instruments supplier’s stock after selling 263,254 shares during the period. Boston Partners owned approximately 0.87% of Haemonetics worth $38,299,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. TFO Wealth Partners LLC raised its stake in Haemonetics by 29,450.0% during the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 589 shares during the period. Covestor Ltd increased its position in shares of Haemonetics by 184.8% in the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after acquiring an additional 438 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Haemonetics in the first quarter worth $86,000. Parkside Financial Bank & Trust increased its position in shares of Haemonetics by 17.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock worth $90,000 after acquiring an additional 156 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Haemonetics in the first quarter worth $114,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Down 0.3 %

HAE traded down $0.28 during trading hours on Friday, reaching $89.85. 504,517 shares of the stock traded hands, compared to its average volume of 401,314. The firm’s fifty day simple moving average is $86.93 and its two-hundred day simple moving average is $84.18. The company has a market cap of $4.58 billion, a price-to-earnings ratio of 39.24, a PEG ratio of 1.64 and a beta of 0.29. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 0.83, a current ratio of 2.56 and a quick ratio of 1.50.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.02. The business had revenue of $343.00 million during the quarter, compared to analyst estimates of $329.53 million. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The business’s revenue was up 12.7% on a year-over-year basis. During the same period last year, the business earned $0.77 EPS. As a group, analysts forecast that Haemonetics Co. will post 4.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Haemonetics

In other Haemonetics news, insider Stewart W. Strong sold 733 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the transaction, the insider now directly owns 15,608 shares in the company, valued at approximately $1,498,992.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Haemonetics news, insider Stewart W. Strong sold 733 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $96.04, for a total transaction of $70,397.32. Following the transaction, the insider now directly owns 15,608 shares in the company, valued at approximately $1,498,992.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stewart W. Strong sold 686 shares of the stock in a transaction on Monday, May 20th. The shares were sold at an average price of $95.11, for a total transaction of $65,245.46. Following the transaction, the insider now owns 18,196 shares in the company, valued at $1,730,621.56. The disclosure for this sale can be found here. Insiders have sold 33,828 shares of company stock worth $3,031,095 in the last ninety days. 1.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

HAE has been the subject of several recent research reports. Barrington Research increased their price objective on shares of Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Needham & Company LLC raised shares of Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a research report on Wednesday, June 12th. Finally, JMP Securities increased their price objective on shares of Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a research report on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.50.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.